3 Overrated Stocks That Concern Us

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.

But not every company with momentum is a long-term winner, and plenty of investors have lost money betting on short-term fads. All that said, here are three overhyped stocks that may correct and some you should consider instead.

Movado (MOV)

One-Month Return: +19.2%

With its watches displayed in 20 museums around the world, Movado (NYSE:MOV) is a watchmaking company with a portfolio of watch brands and accessories.

Why Do We Think MOV Will Underperform?

1. Sales trends were unexciting over the last five years as its 4.7% annual growth was below the typical consumer discretionary company
2. Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
3. Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value

At $21.21 per share, Movado trades at 0.7x forward price-to-sales. If you’re considering MOV for your portfolio, see our FREE research report to learn more.

Exact Sciences (EXAS)

One-Month Return: +45.1%

With a mission to detect cancer earlier when it's more treatable, Exact Sciences (NASDAQ:EXAS) develops and markets cancer screening and diagnostic tests, including its flagship Cologuard stool-based colorectal cancer screening test.

Why Is EXAS Not Exciting?

1. Negative free cash flow raises questions about the return timeline for its investments
2. Negative returns on capital show management lost money while trying to expand the business

Exact Sciences is trading at $100.99 per share, or 120x forward P/E. To fully understand why you should be careful with EXAS, check out our full research report (it’s free for active Edge members).

NeoGenomics (NEO)

One-Month Return: +19.9%

Operating a network of CAP-accredited and CLIA-certified laboratories across the United States and United Kingdom, NeoGenomics (NASDAQ:NEO) provides specialized cancer diagnostic testing services, including genetic analysis, molecular testing, and pathology consultation for oncologists and healthcare providers.

Why Do We Avoid NEO?

1. Revenue base of $709.2 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale
2. Negative returns on capital show that some of its growth strategies have backfired
3. 6× net-debt-to-EBITDA ratio makes lenders less willing to extend additional capital, potentially necessitating dilutive equity offerings

NeoGenomics’s stock price of $12.11 implies a valuation ratio of 78.4x forward P/E. Dive into our free research report to see why there are better opportunities than NEO.

High-Quality Stocks for All Market Conditions

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.